profit from every $100 of sales.
$0$100
ANI Pharmaceuticals
$71.44+0.53% today
-15.5% in 1 year
1-year low $67.411-year high $86.03
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $20.73 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What ANI Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $316 million in 2022 to $883 million in 2025, with $78.3 million of profit last year.
SalesProfit
ANI Pharmaceuticals handed back 9% of the cash it generated last year.
Buybacks $12M
Free cash flow 2025$151M
Bought back its own shares$12M
Paid as dividends$1M
Cash vs. debt$286M vs. $617M
ANI Pharmaceuticals vs. similar companies
ANI Pharmaceuticals grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| ANI Pharmaceuticals | 20.7× · Fair price | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads ANI Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 316 | 487 | 614 | 883 | |
| 178 | 305 | 364 | 542 | |
| -26 | 50 | 2 | 81 | |
| 25 | 107 | 63 | 207 | |
| -48 | 19 | -19 | 78 | |
| -3.05 | 0.85 | -1.04 | 3.32 | |
| 56.1% | 62.7% | 59.3% | 61.4% | |
| -8.1% | 10.2% | 0.4% | 9.2% | |
| -15.1% | 3.9% | -3.0% | 8.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 760 | 904 | 1,284 | 1,440 |
| Cash | 48 | 221 | 145 | 286 |
| Total debt | 287 | 286 | 624 | 617 |
| Total liabilities | 422 | 447 | 856 | 900 |
| 339 | 458 | 429 | 541 | |
| 16 | 18 | 19 | 21 | |
| -4.4% | 5.0% | -0.3% | 7.9% | |
| -14.1% | 4.1% | -4.3% | 14.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -31 | 119 | 64 | 185 | |
| 16 | 19 | 17 | 34 | |
| -48 | 100 | 47 | 151 | |
| Dividends paid | 2 | 2 | 2 | 1 |
| 2 | 5 | 11 | 12 | |
| 15 | 21 | 29 | 38 |
Valuation
- 20.7×
- 7.9×
- –
- 2.9×
- 1.8×
- 10.8×
- 9.4×
- 9.3%
- 4.8%
- 0.0%
Profitability
- 61.4%
- 9.2%
- 8.9%
- 25.7%
- 8.2%
- -0.9%
- 17.3%
- 6.3%
- 10.5%
- 5.6%
Growth
- +40.8%
- –
- +264.2%
- –
- +12.3%
Financial health
- 0.1×
- 0.58
- 23.0%
- 3.9×
- 3.12
- 2.52
- 0.65
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 40%of 964
Bottom 45%of 898
Top 36%of 651
Top 13%of 911
Top 9%of 991
What analysts expect
- Average price target
- $124.00
- Range
- $124.00 – $124.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | 2.05 | 1.28 | +60.2% |
| Feb 27, 2026 | 2.33 | 1.99 | +17.1% |
| Nov 7, 2025 | 2.04 | 1.74 | +17.2% |
| Aug 8, 2025 | 1.80 | 1.38 | +30.4% |
| May 9, 2025 | 1.70 | 1.37 | +24.1% |
| Feb 28, 2025 | 1.63 | 1.41 | +15.6% |
| Nov 8, 2024 | 1.34 | 1.09 | +22.9% |
| Aug 6, 2024 | 1.02 | 0.93 | +9.7% |
News
Reviva Pharmaceuticals GAAP EPS of -$0.17 beats by $0.23Seeking Alpha · Nov 13, 2026Eupraxia Pharmaceuticals reports Q3 resultsSeeking Alpha · Nov 11, 2026Ionis Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha · Nov 6, 2026ANI Pharmaceuticals beats top-line and bottom-line estimates; narrows FY26 outlookSeeking Alpha · Nov 5, 2026Vertex Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha · Nov 1, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
52No pass
Benjamin Graham
45No pass
Philip Fisher
59No pass
Peter Lynch
82Pass
Joel Greenblatt
30No pass
Charlie Munger
43No pass
Terry Smith
52No pass
Questions about ANI Pharmaceuticals
Is ANI Pharmaceuticals a good stock to buy?
A solid business at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the ANI Pharmaceuticals AI analysis
What does ANI Pharmaceuticals do?
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It is in Drug Manufacturers - Specialty & Generic.
Does ANI Pharmaceuticals pay a dividend?
Yes. In 2025 it paid out $1.16 million in dividends.
Is ANI Pharmaceuticals stock halal?
No. ANI Pharmaceuticals does not pass our halal screen: its debt is 38% of its market value, at or above the 33% limit. How we check
How has ANI Pharmaceuticals stock done over the past year?
Down 15.5% over the past twelve months, to $71.44. It traded between $67.41 and $86.03 and is 17.0% below its high.
Who are ANI Pharmaceuticals's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with ANI Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.